**Core Concept**
Folinic acid, also known as leucovorin, is a form of folate used as a medication to counteract the toxic effects of certain chemotherapeutic agents. It is specifically used to rescue methotrexate-induced toxicity by replenishing the body's folate stores and supporting the synthesis of purines and thymidylate.

**Why the Correct Answer is Right**
Folinic acid is used to rescue patients from high-dose methotrexate toxicity by bypassing the enzyme dihydrofolate reductase (DHFR), which is inhibited by methotrexate. By bypassing this enzyme, folinic acid allows for the continued synthesis of tetrahydrofolate, an essential cofactor for DNA synthesis and repair. This is particularly important in patients undergoing high-dose methotrexate therapy for conditions such as leukemia or lymphoma.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because folinic acid is not primarily used to treat iron deficiency anemia. While folate deficiency can exacerbate iron deficiency anemia, folinic acid is not the first-line treatment for this condition.
**Option B:** This option is incorrect because vitamin B12 is a separate vitamin from folate and is not typically used to counteract methotrexate toxicity. Vitamin B12 plays a crucial role in the synthesis of DNA and red blood cells, but it is not directly involved in the rescue of methotrexate-induced toxicity.
**Option C:** This option is incorrect because pyridoxine (vitamin B6) is not directly related to the use of folinic acid in rescuing methotrexate toxicity. While pyridoxine is involved in the synthesis of neurotransmitters and other important biochemical pathways, it is not relevant to the rescue of methotrexate-induced toxicity.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that folinic acid should be administered before methotrexate toxicity becomes severe, as it is most effective in preventing rather than treating toxicity. This highlights the importance of careful monitoring and prompt intervention in patients receiving high-dose methotrexate therapy.

**Correct Answer:** C.